The Effect of Linagliptin on Mitochondrial and Endothelial Function
NCT01969084 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2016-11-18
Summary
Investigators propose to examine the effect of 12 weeks of Linagliptin, a diabetes drug, treatment on inflammation as well as vascular and mitochondrial function in diabetic patients. Investigators hypothesize that Linagliptin will reduce the proinflammatory state, improve endothelial function, increase the blood flow at the muscle microcirculation level and improve mitochondrial function. In this study, investigators will perform tests that evaluate the function of small and large blood vessels by employing ultrasound and laser doppler techniques. In addition MRI scans that evaluate the mitochondrial function of the lower extremity muscles at rest and during exercise will also be employed. Forty subjects with Type 2 diabetes will be studied for twelve weeks and half of them will be randomly assigned to receive linagliptin while the other half will receive placebo. All tests will be performed at the beginning and the end of the study.
Conditions
- Type II Diabetes Mellitus
Interventions
- DRUG
-
Linagliptin
- DRUG
- OTHER
-
Microcirculation testing
The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
- OTHER
-
Macrocirculation testing
Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
- OTHER
-
MRI Scans
Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
Sponsors & Collaborators
-
Beth Israel Deaconess Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2016-07-31
- Completion
- 2016-07-31
Countries
- United States
Study Locations
More Related Trials
-
Effects of Linagliptin on Endothelial Function
NCT02350478 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
NCT02401880 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
NCT00716092 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of DPP4 Inhibition on COVID-19
NCT04341935 ·Status: WITHDRAWN ·Phase: PHASE4
-
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
NCT00996658 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
NCT04088461 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
NCT01214239 ·Status: COMPLETED ·Phase: PHASE3
-
Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes
NCT02015299 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
NCT00819091 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
NCT00954447 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes
NCT03004612 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
NCT02301806 ·Status: UNKNOWN ·Phase: PHASE4
-
Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
NCT02197078 ·Status: COMPLETED
-
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
NCT01408888 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
NCT02597049 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Evaluation of Adverse Reactions in Diabetes
NCT02092597 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
NCT01084005 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
NCT02097342 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment
NCT01903070 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
NCT01087502 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
NCT00734474 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus
NCT01545024 ·Status: UNKNOWN
-
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
NCT02111096 ·Status: TERMINATED ·Phase: PHASE2
-
Sitagliptin Therapy and Kinetics of Inflammatory Markers
NCT02536248 ·Status: COMPLETED ·Phase: PHASE3
-
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
NCT01937598 ·Status: COMPLETED ·Phase: PHASE3